Infinity Bio
BALTIMORE, MD · Biotechnology · 25 employees
Infinity Bio is a technology company that provides detailed insights into the immune system using its proprietary antibody profiling platform. The company’s core technology comprehensively measures the antibody reactome, revealing the targets of individual immune responses against all known human viruses, human proteins (autoimmunity), and allergen proteins. Infinity's assay, MIPSA, was developed
Funding history
- Venture - Series Unknown — $5.0M — Aug 2025
- Series A — $8.0M — Jun 2025
- Seed — $2.0M — Mar 2025
- Seed — $4.5M — Jun 2024
- Seed — $4.5M — Jun 2023
Recent signals
- Mar 18, 2026: Infinity Bio Appoints Brian McKelligon as Chief Executive Officer
- Aug 20, 2025: Raised $5.0M in Venture - Series Unknown
- Jun 18, 2025: Raised $8.0M in Series A
- Mar 11, 2025: Raised $2.0M in Seed
- Jun 03, 2024: Raised $4.5M in Seed
- Jun 26, 2023: Raised $4.5M in Seed
See plans & pricing → Track Infinity Bio’s funding, hiring, and signals — with verified contacts — on Fundz.